Scpharmaceuticals Stock Piotroski F Score

SCPH Stock  USD 3.35  0.11  3.18%   
This module uses fundamental data of Scpharmaceuticals to approximate its Piotroski F score. Scpharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Scpharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Scpharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Scpharmaceuticals Altman Z Score, Scpharmaceuticals Correlation, Scpharmaceuticals Valuation, as well as analyze Scpharmaceuticals Alpha and Beta and Scpharmaceuticals Hype Analysis.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
  
As of now, Scpharmaceuticals' Interest Debt Per Share is increasing as compared to previous years. The Scpharmaceuticals' current Debt To Assets is estimated to increase to 0.43, while Net Debt is projected to decrease to (6.9 M). As of now, Scpharmaceuticals' Payables Turnover is increasing as compared to previous years. The Scpharmaceuticals' current Current Ratio is estimated to increase to 9.18, while Book Value Per Share is projected to decrease to 0.92.
At this time, it appears that Scpharmaceuticals' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Unavailable
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Lower Leverage

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Scpharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Scpharmaceuticals is to make sure Scpharmaceuticals is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Scpharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Scpharmaceuticals' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.110.13
Fairly Down
Slightly volatile
Gross Profit Margin0.580.65
Fairly Down
Slightly volatile
Total Current Liabilities8.3 M13.1 M
Way Down
Slightly volatile
Non Current Liabilities Total29.9 M44.1 M
Way Down
Pretty Stable
Total Assets90.6 M94.5 M
Sufficiently Down
Slightly volatile
Total Current Assets89.4 M92.9 M
Sufficiently Down
Slightly volatile

Scpharmaceuticals F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Scpharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Scpharmaceuticals in a much-optimized way.

About Scpharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

0.92

As of now, Scpharmaceuticals' Book Value Per Share is increasing as compared to previous years.

Scpharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Scpharmaceuticals from analyzing Scpharmaceuticals' financial statements. These drivers represent accounts that assess Scpharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Scpharmaceuticals' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap105.3M130.0M137.3M203.3M241.5M253.6M
Enterprise Value52.7M44.9M80.7M169.6M234.9M246.7M

Scpharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Scpharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Scpharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

About Scpharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Scpharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scpharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scpharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:
Check out Scpharmaceuticals Altman Z Score, Scpharmaceuticals Correlation, Scpharmaceuticals Valuation, as well as analyze Scpharmaceuticals Alpha and Beta and Scpharmaceuticals Hype Analysis.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.95)
Revenue Per Share
0.741
Quarterly Revenue Growth
1.641
Return On Assets
(0.42)
Return On Equity
(1.67)
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.